drugset
Drugs / [14C]-benzo[a]pyrene
last change Feb 2024 re-read 3 minutes ago

[14C]-benzo[a]pyrene

also known as BaP · [14C]-BaP
Investigated by
Lawrence Livermore National Laboratory · National Institute of Environmental Health Sciences (NIEHS) · Oregon State University · Pacific Northwest National Laboratory

Trials 3

today NCT03802721 · Ph 0 NCT03631667 · Ph 0 NCT03318978 · Ph 0
201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT03802721 Jan 2019 → Jan 2024 exposure, dental pulp Oregon State University Completed No outcome recorded
Phase 0 NCT03631667 Oct 2018 → Jan 2024 exposure, dental pulp Oregon State University Completed No outcome recorded
Phase 0 NCT03318978 Apr 2018 → Jan 2024 exposure, dental pulp Oregon State University Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as [14C]-benzo[a]pyrene ClinicalTrials.gov intervention name — accepted as the source's own label NCT03802721 ↗
2

NCT03631667 ↗

NCT03318978 ↗
Known as [14C]-BaP “The pharmacokinetics for \[14C\]-BaP and metabolites will be assessed by UHLPC-Accelerator Mass Spectrometry (AMS, Lawrence Livermore National Laboratory) in plasma and urine...” NCT03318978 ↗
Known as BaP “Cycle 1: Capsule containing 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene (BaP).” NCT03802721 ↗
2

“Cycle 1: Capsule containing 25 ng (2.7 nCi) \[14C\]-benzo\[a\]pyrene (BaP).” NCT03318978 ↗

“Cycle 1: Capsule containing 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene (BaP).” NCT03631667 ↗
Route Oral “following oral doses of 25, 50, 100 or 250 ng” NCT03318978 ↗